U.S., May 9 -- ClinicalTrials.gov registry received information related to the study (NCT06962254) titled 'Imatinib and Trametinib for KRAS-mutated Solid Tumor' on April 08.

Brief Summary: In this pilot trial, participants with unresectable solid cancers harboring KRAS mutations will be provided with a compassionate treatment if their diseases progress after current standard treatments, or there is no available standard treatment. This trial will evaluate the efficacy and safety of the combination of trametinib and imatinib on chemotherapy refractory solid cancers.

Study Start Date: May 10

Study Type: INTERVENTIONAL

Condition: Solid Tumor Cancer

Intervention: DRUG: Imatinib

1. Imatinib is binding to the ATP-binding site of BCR-ABL, ...